Non-Alcoholic Steatohepatitis (NASH) Market Size, Share, Trends, Growth Outlook

Non-Alcoholic Steatohepatitis (NASH) Market is estimated to increase at a growth rate of 42.5% CAGR over the forecast period from 2024 to 2030.

The global Non-Alcoholic Steatohepatitis (NASH) Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Drug (Vitamin E & pioglitazone, Obeticholic Acid, Elafibranor, Selonsertib, Cenicriviroc), By Sales Channel (Hospital pharmacy, Online providers, Retail pharmacy).

An Introduction to Non-Alcoholic Steatohepatitis (NASH) Market in 2024

Non-Alcoholic Steatohepatitis (NASH) has emerged as a critical unmet medical need, driving intensive research and therapeutic development efforts in 2024. The Non-Alcoholic Steatohepatitis Market is witnessing a flurry of activity as pharmaceutical companies race to develop effective treatments for this progressive liver disease, which can lead to cirrhosis, liver failure, and hepatocellular carcinoma. With the rising prevalence of obesity, diabetes, and metabolic syndrome worldwide, NASH has become a major public health concern, prompting stakeholders to expedite clinical trials and regulatory approvals for novel therapeutics. The market is characterized by a diverse pipeline of investigational drugs targeting key pathogenic mechanisms, such as hepatic inflammation, fibrosis, and metabolic dysfunction, with several candidates demonstrating promising efficacy and safety profiles in late-stage trials. Furthermore, there is growing recognition of the need for multidisciplinary approaches encompassing lifestyle modifications, patient education, and early detection strategies to effectively manage NASH and mitigate its long-term complications.

Non-Alcoholic Steatohepatitis (NASH) Market Competitive Landscape

The global Non-Alcoholic Steatohepatitis (NASH) Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Non-Alcoholic Steatohepatitis (NASH) Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Non-Alcoholic Steatohepatitis (NASH) Industry include- AstraZeneca Plc, BioPredictive S.A.S, Cirius Therapeutics, Enzo Biochem Inc, GENFIT SA, Gilead Sciences Inc, GlaxoSmithKline Plc, Intercept Pharmaceuticals Inc, Inventiva S.A., Madrigal Pharmaceuticals Inc, Novo Nordisk AS, Prometheus Laboratories, Siemens Healthineers AG.

Non-Alcoholic Steatohepatitis Market Trend: Advancements in Diagnostic Technologies and Biomarker Discovery

In the Non-Alcoholic Steatohepatitis (NASH) market, a prominent trend is the advancements in diagnostic technologies and biomarker discovery. NASH, a progressive form of non-alcoholic fatty liver disease (NAFLD), is characterized by hepatic inflammation, fibrosis, and hepatocyte injury, with the potential to progress to cirrhosis and hepatocellular carcinoma (HCC). Accurate diagnosis and disease staging are essential for guiding treatment decisions and monitoring disease progression in patients with NASH. Recent advancements in non-invasive diagnostic technologies, such as transient elastography, magnetic resonance imaging (MRI), and serum biomarkers, offer alternatives to liver biopsy for assessing liver fibrosis, inflammation, and steatosis. Additionally, ongoing research efforts focus on identifying novel biomarkers and imaging modalities that provide insights into disease pathogenesis, prognosis, and therapeutic response, driving innovation and improving diagnostic accuracy in the NASH market.

Non-Alcoholic Steatohepatitis Market Driver: Rising Prevalence of Obesity and Metabolic Syndrome

The primary market driver for NASH is the rising prevalence of obesity and metabolic syndrome. NASH is closely linked to metabolic risk factors, including obesity, type 2 diabetes, dyslipidemia, and insulin resistance, which contribute to hepatic steatosis, inflammation, and fibrosis. The global obesity epidemic, coupled with sedentary lifestyles and unhealthy dietary habits, has led to an increase in the prevalence of metabolic disorders and NAFLD/NASH worldwide. As the burden of obesity and metabolic syndrome continues to rise, there is a parallel increase in the incidence and prevalence of NASH and its associated complications, driving the demand for effective diagnostic tools, therapeutic interventions, and healthcare services to address the growing public health challenge posed by NASH.

Non-Alcoholic Steatohepatitis Market Opportunity: Development of Disease-Modifying Therapies and Combination Therapies

An emerging opportunity in the NASH market lies in the development of disease-modifying therapies and combination therapies. While lifestyle modifications and weight loss remain the cornerstone of NASH management, there is a significant unmet need for pharmacological interventions that target the underlying pathophysiology of the disease and halt disease progression. Disease-modifying therapies, including pharmacological agents that address hepatic steatosis, inflammation, fibrosis, and metabolic dysregulation, offer promising treatment options for patients with NASH. Additionally, the complexity of NASH pathogenesis and the multifactorial nature of metabolic syndrome suggest that combination therapies targeting multiple pathways may be more effective in achieving sustained therapeutic benefits. Collaborative research efforts between academia, pharmaceutical companies, and regulatory agencies are essential for advancing the development and regulatory approval of disease-modifying and combination therapies, addressing unmet medical needs and improving patient outcomes in the NASH market.

Non-Alcoholic Steatohepatitis Market Share Analysis: Obeticholic Acid is the fastest growing market segment over the forecast period to 2030

Among the drugs targeting Non-Alcoholic Steatohepatitis (NASH), Obeticholic Acid emerges as the fastest-growing segment. This growth can be attributed to several factors, including its proven efficacy in clinical trials, increasing prevalence of NASH, and growing acceptance among healthcare providers as a viable treatment option. Obeticholic Acid works by targeting the farnesoid X receptor (FXR), which regulates bile acid synthesis and glucose metabolism, key pathways implicated in NASH pathogenesis. Clinical studies have demonstrated its ability to improve liver histology and reduce fibrosis progression in NASH patients, positioning it as a promising therapeutic agent in the management of this complex liver disease. Moreover, the accelerated pace of drug development and regulatory approvals in the NASH market has propelled the adoption of Obeticholic Acid by healthcare professionals seeking effective pharmacological interventions for their patients. With an expanding market presence across hospital and retail pharmacies, alongside increasing accessibility through online providers, Obeticholic Acid is poised to experience robust growth in the foreseeable future, playing a pivotal role in addressing the unmet medical needs of individuals suffering from NASH.

Non-Alcoholic Steatohepatitis (NASH) Market Segmentation

By Drug
Vitamin E & pioglitazone
Obeticholic Acid
Elafibranor
Selonsertib
Cenicriviroc
By Sales Channel
Hospital pharmacy
Online providers
Retail pharmacy
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Non-Alcoholic Steatohepatitis (NASH) Companies

AstraZeneca Plc
BioPredictive S.A.S
Cirius Therapeutics
Enzo Biochem Inc
GENFIT SA
Gilead Sciences Inc
GlaxoSmithKline Plc
Intercept Pharmaceuticals Inc
Inventiva S.A.
Madrigal Pharmaceuticals Inc
Novo Nordisk AS
Prometheus Laboratories
Siemens Healthineers AG
* List not Exhaustive

Reasons to Buy the Non-Alcoholic Steatohepatitis (NASH) Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Non-Alcoholic Steatohepatitis (NASH) Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Non-Alcoholic Steatohepatitis (NASH) Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Non-Alcoholic Steatohepatitis (NASH) Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Non-Alcoholic Steatohepatitis (NASH) Market Size Outlook, $ Million, 2021 to 2030
3.2 Non-Alcoholic Steatohepatitis (NASH) Market Outlook by Type, $ Million, 2021 to 2030
3.3 Non-Alcoholic Steatohepatitis (NASH) Market Outlook by Product, $ Million, 2021 to 2030
3.4 Non-Alcoholic Steatohepatitis (NASH) Market Outlook by Application, $ Million, 2021 to 2030
3.5 Non-Alcoholic Steatohepatitis (NASH) Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Non-Alcoholic Steatohepatitis (NASH) Industry
4.2 Key Market Trends in Non-Alcoholic Steatohepatitis (NASH) Industry
4.3 Potential Opportunities in Non-Alcoholic Steatohepatitis (NASH) Industry
4.4 Key Challenges in Non-Alcoholic Steatohepatitis (NASH) Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Non-Alcoholic Steatohepatitis (NASH) Market Outlook by Segments
7.1 Non-Alcoholic Steatohepatitis (NASH) Market Outlook by Segments, $ Million, 2021- 2030
By Drug
Vitamin E & pioglitazone
Obeticholic Acid
Elafibranor
Selonsertib
Cenicriviroc
By Sales Channel
Hospital pharmacy
Online providers
Retail pharmacy
8 North America Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Outlook To 2030
8.1 Introduction to North America Non-Alcoholic Steatohepatitis (NASH) Markets in 2024
8.2 North America Non-Alcoholic Steatohepatitis (NASH) Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Non-Alcoholic Steatohepatitis (NASH) Market size Outlook by Segments, 2021-2030
By Drug
Vitamin E & pioglitazone
Obeticholic Acid
Elafibranor
Selonsertib
Cenicriviroc
By Sales Channel
Hospital pharmacy
Online providers
Retail pharmacy
9 Europe Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Outlook To 2030
9.1 Introduction to Europe Non-Alcoholic Steatohepatitis (NASH) Markets in 2024
9.2 Europe Non-Alcoholic Steatohepatitis (NASH) Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Non-Alcoholic Steatohepatitis (NASH) Market Size Outlook by Segments, 2021-2030
By Drug
Vitamin E & pioglitazone
Obeticholic Acid
Elafibranor
Selonsertib
Cenicriviroc
By Sales Channel
Hospital pharmacy
Online providers
Retail pharmacy
10 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Markets in 2024
10.2 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Market size Outlook by Segments, 2021-2030
By Drug
Vitamin E & pioglitazone
Obeticholic Acid
Elafibranor
Selonsertib
Cenicriviroc
By Sales Channel
Hospital pharmacy
Online providers
Retail pharmacy
11 South America Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Outlook To 2030
11.1 Introduction to South America Non-Alcoholic Steatohepatitis (NASH) Markets in 2024
11.2 South America Non-Alcoholic Steatohepatitis (NASH) Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Non-Alcoholic Steatohepatitis (NASH) Market size Outlook by Segments, 2021-2030
By Drug
Vitamin E & pioglitazone
Obeticholic Acid
Elafibranor
Selonsertib
Cenicriviroc
By Sales Channel
Hospital pharmacy
Online providers
Retail pharmacy
12 Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Markets in 2024
12.2 Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Market size Outlook by Segments, 2021-2030
By Drug
Vitamin E & pioglitazone
Obeticholic Acid
Elafibranor
Selonsertib
Cenicriviroc
By Sales Channel
Hospital pharmacy
Online providers
Retail pharmacy
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AstraZeneca Plc
BioPredictive S.A.S
Cirius Therapeutics
Enzo Biochem Inc
GENFIT SA
Gilead Sciences Inc
GlaxoSmithKline Plc
Intercept Pharmaceuticals Inc
Inventiva S.A.
Madrigal Pharmaceuticals Inc
Novo Nordisk AS
Prometheus Laboratories
Siemens Healthineers AG
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Drug
Vitamin E & pioglitazone
Obeticholic Acid
Elafibranor
Selonsertib
Cenicriviroc
By Sales Channel
Hospital pharmacy
Online providers
Retail pharmacy